Takeda Research & Development Fact Sheet

At Takeda, we are a forward-looking, world-class R&D organization that unlocks innovation and delivers transformative therapies to patients. By focusing R&D efforts on four therapeutic areas and other targeted investments, we push the boundaries of what is possible in order to bring life-changing therapies to patients worldwide.

Our Focus Areas

ONCOLOGY

We endeavor to deliver novel medicines to patients with cancer worldwide through our three strategic pillars: hematologic malignancies, lung cancer and immuno-oncology (I/O).

11
clinical-stage assets

GASTROENTEROLOGY (GI)

We work to restore Life to Living for patients suffering with GI diseases across our core disease areas: inflammatory bowel disease, celiac and other luminal gut diseases, motility disorders and liver diseases.

9
clinical-stage assets

RARE DISEASES

We aspire to transform the treatment of rare immunology, rare hematology and lysosomal storage disorders and expand our focus to bring transformative or curative therapies to other rare diseases.

7
clinical-stage assets

NEUROSCIENCE

Our mission is to bring innovative medicines to patients suffering from neurologic and psychiatric diseases for whom there are no treatments available.

9
clinical-stage assets

A Diverse & Dynamic Pipeline[1]

40
NEW MOLECULAR ENTITY CLINICAL STAGE ASSETS[2]

~50%
PIPELINE WITH ORPHAN DRUG DESIGNATION

MODALITY-DIVERSE RESEARCH PROJECTS

Our Research engine is investing in next-generation technologies beyond small molecules to bring a new wave of innovative treatments to patients.



PUTTING PATIENTS FIRST

Takeda's R&D patient access programs, knowledge sharing and capacity building programs have been recognized as ***Industry Best Practices*** by the Access to Medicine Foundation.

R&D ESTABLISHED:

20+ PARTNERSHIPS

50+ INITIATIVES

with non-governmental organizations since 2015 to support local R&D and healthcare capacity building in underserved countries and communities.

EXTERNALLY ORIENTED MINDSET

We seek innovation and partner to nurture it, wherever it resides. We have diverse partnership models, each created with aligned incentives and designed to leverage what we each do best - together.

Since FY16

200+ Active Partnerships

45+ Venture Investment Financings

25+ New Company Creations

1 Pipeline as of July 31, 2019
2 Includes assets in our four focus Therapeutic Areas and targeted R&D investments in Plasma-Derived Therapies and Vaccines

© Takeda Pharmaceutical Company Limited. All rights reserved. July 2019.

Takeda

Our Global Footprint

Employees Worldwide

4,400+

Regional Centers*

OSAKA, JAPAN
TOKYO, JAPAN

SHANGHAI, CHINA
SINGAPORE

ZÜRICH, SWITZERLAND
VIENNA & ORTH, AUSTRIA

**Each regional center also has a secondary support team in the general vicinity to support local regulatory engagement and sustain other R&D activities.*

LOCAL SITES
Takeda operates in additional countries for specific R&D functions and/or based on legal requirements.

R&D Leadership Team

Andy Plump
President, Research & Development

Asit Parikh
Head, Gastroenterology Therapeutic Area Unit

Emiliangelo Ratti
Head, Neuroscience Therapeutic Area Unit

Phil Rowlands
Head, Oncology Therapeutic Area Unit

Dan Curran
Head, Rare Diseases Therapeutic Area Unit

Steve Hitchcock
Head, Research

Nenad Grmusa
Head, Center for External Innovation

Georgia Keresty
R&D Chief Operating Officer

Wolfram Nothaft
Chief Medical Officer

Wolfgang Hackel
Head, Global R&D Finance

Jeremy Chadwick
Head, Regulatory, GPSE, Development Operations & Clinical Supply Chain

Anne Heatherington
Head, Data Sciences Institute

Stefan Wildt
Head, Pharmaceutical Sciences & Translational Engine, Cell Therapies

Erika Marder
Head, Global R&D Human Resources

Colleen Beauregard
Head, Global R&D Communications

Toshio Fujimoto
General Manager, Shonan Health Innovation Park (iPark)

© Takeda Pharmaceutical Company Limited. All rights reserved. July 2019.

Takeda